Figure 9.

Renal cell proliferation in acute kidney injury (AKI) mice untreated or treated with MSCs or MVs. (A) Quantification of BrdU-positive cells/high power field (hpf). BrdU was injected intraperitoneally for 2 successive days before mice being killed. (B) Quantification of PCNA-positive cells/hpf. All quantitative data were obtained from eight different mice for experimental conditions. ANOVA with Dunnet's multicomparison test: *P < 0.05 MSC- or MV-injected mice versus AKI control mice. (C) Representative micrographs of PCNA or BrdU uptake staining performed on sections of kidneys 5 and 8 d after glycerol treatment (2 and 5 d after vehicle or MSC or MV injection). Magnification: ×400. AKI, AKI untreated with MVs; AKI+MV, AKI treated with 15 μg MSC-derived MVs; AKI+RNase MV, AKI treated with 15 μg RNase inactivated MSC-derived MVs; AKI+MSC, AKI treated with 75,000 MSCs; AKI+MV sHA, AKI treated with 15 μg MSC-derived MVs preincubated with sHA; AKI+F-MV, AKI treated with 15 μg fibroblast-derived MVs.